Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

Published
13 May 2013
From
Janssen press release
New and experimental hepatitis C treatment
Gilead Reports Interim Data From Phase 2 LONESTAR Study

Company Plans to Initiate Phase 3 Study Evaluating Eight and 12 Weeks of Therapy with Sofosbuvir and Ledipasvir for the Treatment of Chronic Hepatitis C.

Published
03 May 2013
From
Gilead press release
New and experimental hepatitis C treatment
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

Published
01 May 2013
From
PR Newswire
New and experimental hepatitis C treatment
Gilead-Bristol Hepatitis C Combo Cures 100% of Patients in Study

A combination of hepatitis C drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) cured 100 percent of patients in a trial, showing the success of a cocktail that doctors say they want yet may never be approved.

Published
28 April 2013
From
Businessweek
New and experimental hepatitis C treatment
Sofosbuvir Offers High Cure Rate For Two Hepatitis C Subtypes -

Sofosbuvir, a new drug, is offering impressive cure rates for Hepatitis C patients with two subtypes of the disease - genotypes 2 and 3, according to researchers led by Weill Cornell Medical College.

Published
24 April 2013
From
Medical News Today
New and experimental hepatitis C treatment
Investigational compound faldaprevir shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C

In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12).

Published
24 April 2013
From
Boehringer-Ingelheim press release
New and experimental hepatitis C treatment
Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Presented at EASL 23-28 April in Amsterdam Read more: Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Pres

These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin.

Published
24 April 2013
From
Medivir press release
New and experimental hepatitis C treatment
AbbVie hepatitis C drugs knock out virus at eight weeks

A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.

Published
24 April 2013
From
Yahoo News
New and experimental hepatitis C treatment
Bristol-Myers oral hepatitis C regimen looks competitive -study

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Published
24 April 2013
From
Reuters
New and experimental hepatitis C treatment
The Hepatitis C Drug Pipeline Report: A Groundswell to Become a Sea Change

Frantic competition between the major pharmaceutical players has accelerated progress on new hepatitis C virus (HCV) therapies to a breakneck speed.

Published
19 April 2013
From
Hep: Your Guide to Hepatitis
← First12345...25Next →

Filter by country